Optherion Announces Presentation at ARVO 2009 Annual Meeting

“A Clinical Study to Identify a Population with Blood-Based Biomarkers for Age-Related Macular Degeneration (AMD)”

NEW HAVEN, Conn., April 29 /PRNewswire/ — Optherion, Inc., a company developing novel molecular diagnostics and treatments for dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that it will be reporting data from its diagnostics development program at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Ft Lauderdale, FL, from May 3-7, 2009.

The title of the poster presentation is “A Clinical Study to Identify a Population with Blood-Based Biomarkers for Age-Related Macular Degeneration (AMD)”

Authors: D. Weaver, G. Ligon, K. Hade, L. Perlee, D. Grant, M. Patel, M. Modi.

Sunday, May 03, 2009, 11:15 AM – 1:00 PM

Poster #744/D798 Location Hall B/C

Colin J. Foster, Optherion’s President and CEO, said: “We are pleased with the results from this prospective clinical study in subjects across a broad age range that validate earlier reports describing the population distribution of genetic markers of AMD. This study assists us in completing the development of a genetic test that will inform prognosis and risk of AMD.”

About Optherion:

Optherion, Inc. is a private innovative biotechnology company that is developing protein therapeutics and molecular diagnostics for the management of dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion’s proprietary technologies are based on landmark scientific discoveries linking certain genes to AMD.

SOURCE Optherion, Inc.